GLP-1 medications like Semaglutide and Tirzepatide have been clinically proven to help patients lose 15-20% of body weight. Prescribed by our providers, shipped to your door.
GLP-1 receptor agonists (Semaglutide and Tirzepatide) work by mimicking a natural hormone called glucagon-like peptide-1, which is released in your gut after eating. These medications activate GLP-1 receptors in the brain's appetite control center, leading to reduced hunger, earlier feelings of fullness, and decreased food cravings.
In landmark clinical trials (STEP, SURMOUNT), patients on Semaglutide lost an average of 15% of their body weight, while Tirzepatide patients achieved up to 22.5% — results previously only seen with bariatric surgery.
At Phlex Meds, our providers carefully titrate your dose over 8-12 weeks to minimize side effects and optimize results. Every patient receives a personalized nutrition framework, ongoing lab monitoring, and direct provider messaging.
All medications are compounded by licensed 503B pharmacies using FDA-approved ingredients.
The most widely prescribed GLP-1 medication for weight management. Same active ingredient as Ozempic® and Wegovy®, compounded at our licensed 503B pharmacy for significantly lower cost.
The newest and most effective weight loss injectable available. Dual-action GIP and GLP-1 receptor agonist (same active ingredient as Mounjaro® and Zepbound®). Superior weight loss results in head-to-head trials.
Methylcobalamin (B12), MIC lipotropic complex (Methionine, Inositol, Choline), and L-Carnitine to boost energy, support fat metabolism, and prevent nutrient deficiencies during caloric deficit.
From intake to treatment — simple, fast, and provider-supervised.
5-minute online questionnaire reviewed by our clinical team within 24 hours.
LabCorp walk-in or mobile draw. Video consultation to review results and build your protocol.
Medications ship in discreet packaging within 2 business days. Ongoing monitoring included.
Results vary by individual. Here is a typical timeline based on clinical data.
Noticeable reduction in hunger and food cravings. Many patients report feeling satisfied with smaller portions and fewer snacking urges.
Most patients lose 5-8% of body weight during initial titration. Clothes fit differently. Energy levels improve as metabolic function optimizes.
10-15% body weight reduction is common. Lab improvements visible: A1C, triglycerides, blood pressure. Body composition changes become dramatic.
15-22% total body weight loss. Provider evaluates maintenance dosing. Metabolic health markers typically normalize. Sustained lifestyle changes established.
No hidden fees. No surprise bills. Cancel anytime.
Semaglutide from $149/mo. Tirzepatide from $249/mo. Includes medication, labs, and provider access.
GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors. In animal studies, semaglutide and tirzepatide produced thyroid C-cell tumors. It is unknown whether these drugs cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, and injection site reactions. GI side effects are most common during dose titration and typically subside. More serious: pancreatitis, gallbladder events, hypoglycemia (in diabetic patients on sulfonylureas/insulin), and allergic reactions.
Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease, and Type 1 diabetes.
See full safety disclosures for complete prescribing information.
Both are GLP-1 receptor agonists. Semaglutide (same as Ozempic/Wegovy) targets only GLP-1 receptors. Tirzepatide (same as Mounjaro/Zepbound) is a dual-action drug targeting both GLP-1 and GIP receptors, typically producing slightly greater weight loss (up to 22.5% vs 15% in clinical trials). Your provider will recommend the best option based on your goals and medical history.
In clinical trials, patients on Semaglutide lost an average of 15% of body weight, and Tirzepatide patients lost up to 22.5%. Individual results vary based on starting weight, diet, exercise, and dosing. Most patients see noticeable results within 4-8 weeks.
Nausea is the most common side effect and is usually mild to moderate. Our providers use a slow titration protocol (starting at the lowest dose and increasing over 8-12 weeks) to minimize GI side effects. Most patients find nausea improves significantly after the first few weeks.
Our compounded medications contain the same active ingredients (semaglutide and tirzepatide) but are manufactured by licensed 503B compounding pharmacies. This allows us to offer them at significantly lower prices while maintaining pharmaceutical quality standards.
Weight regain is possible after discontinuation, as appetite-suppressing effects wear off. Our providers work with you to establish sustainable lifestyle modifications during treatment, and can discuss maintenance dosing strategies for long-term management.
Yes. We require baseline labs including CMP, lipid panel, A1C, thyroid function, and CBC. Labs are repeated at 3-month intervals to monitor metabolic improvements and safety markers. We coordinate walk-in lab draws through our LabCorp partnership.